ESR1 and breast cancer: Emerging options, such as Selective Estrogen Receptor Degraders (SERDs) like Fulvestrant or Proteolysis Targeting Chimeras (PROTACs), provide primary therapeutic avenues for postmenopausal women facing endocrine-resistant BC or advanced metastatic ERα+ BC [8,9,10,11].